DxS Appoints David Jackson as Vice President of Business Development and Licensing
DxS Ltd has announced the appointment of Dr. David Jackson as Vice President of business development and Licensing. Dr. Jackson will be responsible for planning and executing business development efforts for the companion diagnostics and technology licensing business units of DxS and will be based in the US.
Dr. Jackson was most recently with Response Genetics, Inc. as Executive Vice President and has extensive consulting experience in personalized medicine. Before this he was president and chief operating officer at of CryoFluor Therapeutics. During his career Jackson has held positions including private and public company investment analyst, product and corporate development, and Intellectual Property management roles. He holds a PhD in Physiology and Medicine from Boston University School of Medicine, is trained as a US Patent Agent and holds several US securities licenses.
Other news from the department people
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
Melinda_Gates
SYGNIS strengthens IP position in the treatment of acute stroke with AX200 in the US
Merck Decides Not to Pursue Evofosfamide Further in Soft Tissue Sarcoma and Pancreatic Cancer
Researchers optimizing progesterone for brain injury treatment - New approaches include adding vitamin D and using water-soluble analogues
The ultimate decoy - Scientists find protein that helps bacteria misdirect immune system
Researchers rapidly turn bacteria into biotech factories
PBL InterferonSource founder, Sidney Pestka, MD, to receive 'Distinguished Service Award' from 'ISICR'
Fabry's_disease
